On a white board in his office earlier this year, Trump trade adviser Peter Navarro made a list of potential companies that could manufacture pharmaceuticals in the U.S.

He separated them into three columns, one for each stage of the production process. Eastman Kodak Co. stood out, overlapping two of the three columns. The way Navarro saw it, he recalled, Kodak could help produce the ingredients to jump-start generic drug production and ease the country’s reliance on foreign supplies.